The objective of this study was to use the established xenograft model of human melanoma (C8161.9) to test a pharmacological approach to the effect of the metastasis suppressor KISS1. A KISS1 analog was used to inhibit the metastatic development of C8161.9 cells in nude mice. Further experiments were performed to test the validity of the C8161.9 model and test the connection between KISS1 expression and loss of metastatic potential. New clones of C8161.9 cells were obtained, with or without KISS1 expression, and were tested for metastasis formation. The absence of benefit in survival with the KISS1 analog compared with PBS prompted us to revisit the C8161.9 model. We found that the cells expressing KISS1, used in the previous study and obtained by transfection and single-cell cloning, were defective for both formation of orthotopic tumors and metastases. In mixing experiments, these cells could not suppress orthotopic tumor growth of KISS1-negative C8161.9 cells, suggesting that the suppression of metastasis by C8161.9-KISS1 cells may be intrinsic to the selected clone rather than related to KISS1 expression. Isolation of clones from parental C8161.9 cells in soft agar yielded cell populations that phenotypically and genotypically mimicked the KISS1-positive clone. In addition, new clones expressing KISS1 did not show any decrease in metastatic growth. These data demonstrate the heterogeneity of cell types in the C8161.9 cell line and the high risk of artifact linked to single-cell selection. A different xenograft model will be necessary to evaluate the use of KISS1 analogs as antimetastatic therapy. Melanoma Res 22:140-150 c
Introduction
KISS1 was identified as a metastasis suppressor gene in human malignant melanoma cells [1, 2] . As opposed to tumor suppressors, metastasis suppressors do not inhibit the growth of primary tumors, but specifically target the spread of tumor cells to distant organs and the establishment of secondary lesions. These metastasis suppressors can interfere with any step of the metastatic cascade, including invasion, angiogenesis, migration and homing, intravasation, and survival and proliferation in a new environment [3] . KISS1 was originally identified in experiments in which transfer of human chromosome 6 to metastatic melanoma cells suppressed metastasis in a mouse xenograft model [1, 2] . The gene was identified by subtractive hybridization and differential display, and was sufficient to suppress the metastatic phenotype of several human cell lines including breast cancer [4] and ovarian carcinoma [5] in mouse xenograft experiments. In clinical studies, the absence or reduced expression of KISS1 has been linked to higher grade and/or poor prognosis in several malignancies including melanoma [6, 7] , carcinoma of the ovary [8, 9] , stomach [10, 11] , urinary bladder [12] esophagus [13] , lung [14] , and pancreas [15, 16] .
KISS1 encodes a secreted protein that is sequentially proteolytically processed to generate multiple polypeptides ranging from 10 to 54 amino acids called kisspeptins (KPs) that share the same amidated C-terminus [17] [18] [19] [20] . Although other peptidic fragments are generated during this maturation process, the biological activity of KISS1 is thought to reside with KP. Their action is mediated through binding to and activation of GPR54, a G proteincoupled receptor, also known as AXOR12 and hOT7T175 and coupled to Ga q [17] [18] [19] [20] . GPR54 activation by KP was shown to block chemotaxis to fetal bovine serum, activate extracellular signal-regulated kinase (ERK1/2), induce formation of stress fibers, phosphorylate focal adhesion complex, decrease expression of matrix metalloproteinase 9, and reduce cell proliferation in receptor transfectants [17, 19, 21] . We have shown previously that activation of GPR54 by KP10 inhibited chemotaxis induced by stromal cell-derived factor 1 (SDF-1)/CXCL12 and its receptor CXCR4 [22] , a mechanism shown in several models to be involved in the migration of CXCR4 + tumor cells to the organs that secrete its ligand such as the lungs, liver, brain, and bones [23] . Activation of GPR54 suppressed Akt phosphorylation by CXCR4 [22] . We recently demonstrated a number of cellular events resulting from GPR54 activation, including suppression of the phosphorylation of Akt following activation of their respective receptor tyrosine kinase by epidermal growth factor (EGF) and insulin, induction of apoptosis, expression of TNF-a [24] , as well as profound modifications of the actin cytoskeleton through RhoA and Rho-associated kinase activation [25] .
The human melanoma cell line C8161.9 was used for the initial description of the antimetastatic properties of KISS1 [1] . In xenograft experiments in nude mice, the secretion of KP by a C8161.9 clone was shown to have a remarkable capacity to reduce metastasis to the lungs, eyes, bones, and kidneys by keeping tumor cells quiescent after dissemination and seeding in secondary organs [26] . Furthermore, this model is especially interesting in that, although the metastatic growth of C8161.9 cells is suppressed by the secretion of KPs, the cells do not express GPR54 [26] . This suggests that KPs have the capacity to act on the microenvironment of tumor cells rather than on the tumor cells themselves [27] . This property could establish KPs or synthetic analogs as prime candidates to be a therapeutic option for the treatment of metastatic disease as they could be used even after dissemination from the primary tumor has occurred, a property that would be especially desirable for the treatment of melanoma. To test this hypothesis, we used a recently developed analog of KP with vastly improved stability to inhibit metastatic growth of C8161.9 cells. The results of these experiments prompted us to revisit the C8161.9 xenograft model. We found that the remarkable antimetastatic properties of KISS1 in that model rely largely on an artifact of clonal selection rather than on KISS1 expression.
Methods

Cell lines and transfections
Parental C8161.9, C8161.9 transfected with an empty pcDNA3 plasmid, selected with G418, and then transduced with a lentivirus encoding enhanced green fluorescent protein (EGFP; C8161.9-pc3), and C8161.9 transfected with pcDNA3 coding for KISS-FLAGmetastin (KFM; a version of KISS1 incorporating a FLAG tag), cloned and then transduced with a lentivirus encoding EGFP (C8161.9-KFM) were described previously [26] . Whereas, C8161.9-pc3 cells are a polyclonal population derived from the parental cells by antibiotic selection (G418), C8161.9-KFM cells are a single-cell clone obtained by antibiotic selection (also G418) followed by limiting dilution and screening for secretion of KISS1. These different cell lines were kindly provided by Dr Danny Welch (UAB, Birmingham, Alabama, USA).
The open reading frame coding for KFM was amplified by PCR from the DNA purified from C8161.9-KFM cells and subcloned in pcDNA3.1 (Invitrogen, Carlsbad, California, USA) with the G418 or hygromycin selection marker. The correct sequence was verified by Sanger sequencing. Parental C8161.9 cells (for pcDNA3.1-G418) and C8161.9-pc3 (for pcDNA3.1-Hygro) were transfected using lipofectamine complemented with LTX reagent (Invitrogen) according to the manufacturer's instructions and selected with the appropriate antibiotics for 2 weeks before cloning.
Kisspeptin analogs (4-Fluorobenzoyl)-Phe-Gly-Leu-Arg-Trp-NH2 (FTM145) and FTM145-carboxylate (nonamidated) have been described previously [28] . Lyophilized compounds were dissolved in dimethyl sulfoxide at 12.5 mmol/l, diluted in PBS at 250 mmol/l, and sterile filtered. Single-use aliquots were prepared for in-vivo experiments.
Western blotting
Western blotting was performed as described previously [22] . Briefly, transfectants of 293 cells with stable expression of GPR54 were seeded in 35 mm plates, starved overnight in serum-free medium, then exposed to log dilutions of KP10, FTM145, or FTM145-carboxylate for 5 min. Cell lysates were prepared in SDS sample buffer. Western blots were incubated first with antibodies to total ERK1/2 or phospho-ERK1/2 (Cell Signaling Technology, Danvers, Massachusetts, USA), then with secondary antibodies labeled with peroxidase (Jackson ImmunoResearch, West Grove, Pennsylvania, USA). Western blots were finally incubated with a chemiluminescent substrate (ECL-Plus; Amersham, GE-Healthcare, Piscataway, New Jersey, USA) and analyzed with a LAS-4000 digital imaging system (GE-Healthcare).
Soft-agar assay
The bottom layer consisted of 5 ml of 2 Â Dulbecco's modification of essential medium/Ham's F-12 (DMEM/ F-12) mixed at 401C with 5 ml of a 1% solution of agar noble (BD Biosciences, Sparks, Maryland, USA) in H 2 O and was layered in a 100 mm tissue-culture dish. For the top layer, 1.5 Â 10 4 cells were added to 5 ml of 2 Â DMEM/F-12 mixed with 5 ml of a 0.7% solution of agar in H 2 O (0.35% final concentration of soft agar). After solidification, 10 ml of complete liquid medium was added. Medium was replaced every 3 days for 4 weeks. Colonies were photographed using an inverted microscope or an ImageQuant LAS-4000 digital imaging system (GEHealthcare, Piscataway, New Jersey, USA). For clone isolation, colonies were extracted using 1000 ml sterile tips and placed in warm trypsin-ethylenediaminetetraacetic acid in medium. Repeated pipetting was used to dissociate the colonies, and the cells were plated in tissue-culture dishes in complete growth medium.
Detection and quantification of secreted KISS-FLAGmetastin by enzyme-linked immunosorbent assay dishes. Cells were grown for 48 h at 371C in 5% CO 2 . Conditioned media were then collected and cleared by centrifugation at 2000 g for 5 min. Enzyme-linked immunosorbent assay (ELISA) plates (Maxisorp, NalgeNunc, Rochester, New York, USA) were coated for 1 h at room temperature (RT) with 100 ml of a mouse monoclonal antibody specific for KISS1 (clone 1A5 or 6A4; kindly provided by Dr MaryAnn Accavitti-Loper, UAB), diluted at 10 mg/ml in PBS. After blocking for 1 h with tris buffered saline (TBS) containing 5% BSA, antigen capture was performed with 200 ml of conditioned medium for 1.5 h at RT, followed by detection with M2 anti-FLAG antibody conjugated to peroxidase (Sigma, St Louis, Missouri, USA) diluted 1 : 5000 in TBS 1% BSA. The substrate (200 ml, SigmaFast, Sigma) was added for 30 min and the reaction was stopped with 50 ml of 1 N HCl. Absorbance was measured at 490 nm using a spectrophotometer (BioTek, Winooski, Vermont, USA). The background was determined using a conditioned medium obtained with C8161.9-pc3 cells and was identical to the signal obtained with TBS-BSA alone.
Detection of intracellular KISS1 by flow cytometry
Cells were detached with trypsin-ethylenediaminetetraacetic acid, fixed in PBS containing 4% paraformaldehyde (PFA) for 1 h at RT, washed four times in PBS, then permeabilized for 5 min in PBS containing 0.1% Triton X-100. PFA was quenched with 100 mmol/l glycine in PBS for 30 min, followed by blocking in PBS containing 1% BSA and 10% goat serum for 1 h at RT. Cells were incubated with the 1A5 anti-KISS1 antibody or a control IgG (SouthernBiotech, Birmingham, Alabama, USA; both 2 mg/ml in PBS containing 1% BSA and 10% goat serum) for 90 min at RT, followed by overnight incubation at 41C with F(ab 0 )2 goat anti-mouse IgG labeled with phycoerythrin (10 mg/ml; Jackson ImmunoResearch, West Grove, Pennsylvania, USA). Samples were analyzed on an FACS Sort flow cytometer and Cell Quest software (BD Biosciences, San Jose, California, USA).
Quantitative real-time polymerase chain reaction
Total RNA was extracted from cell lines using the mirVana miRNA isolation kit (Ambion, Austin, Texas, USA), and quality was assessed using an RNA 6000 Nano kit and a Bioanalyser 2100 (Agilent Technologies, Santa Clara, California, USA). For cDNA synthesis, 500 ng of RNA was used with the Enhanced Avian First Strand Synthesis kit (Sigma). Quantitative real-time PCR (qPCR) was performed on a Lightcycler 480 (Roche, Indianapolis, Indiana, USA) with HotStartIT SYBR Green qPCR mastermix (USB, Cleveland, Ohio, USA) using the following primers: forward 5 0 -actcactggtttcttg gcagc-3 0 , reverse 5 0 -accttttctaatggctcccca-3 0 . Cycling conditions were 951C for 3 min, 40 cycles of 951C for 10 s, 601C for 20 s, and 721C for 30 s, followed by a melting curve from 45 to 951C. A standard curve was obtained using serial dilutions of the pcDNA3.1-KFM plasmid.
Jurkat cells transfected with GPR54 were used as a negative controls because the presence of very low concentrations of KP was shown to induce apoptosis in these cells.
In-vivo experiments
Nude mice that were 3-4 weeks old (Harlan, Indianapolis, Indiana, USA) were used for all experiments. For orthotopic tumor formation, mice were injected intradermally with 2 Â 10 5 cells in 50 ml Hank's balanced salt solution using a Hamilton syringe and a 30 G needle. Mice were euthanized after 5 weeks and tumor size was measured using a caliper. For metastatic tumor formation, 5 Â 10 5 cells were injected in the lateral tail vein in 100 ml of Hank's balanced salt solution using an insulin syringe and a 31 G needle. Antimetastatic activity of FTM145 was assessed by injecting 150 ml of a 250 mmol/l solution in PBS, an amount expected to generate an estimated peak concentration of about 20 mmol/l in the extracellular space in 15-20 g animals. Mice were euthanized after 5 weeks or when moribund for survival experiments. All experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee at Thomas Jefferson University. Animals were dissected and lungs were fixed in PBS containing 4% PFA for 24 h before being processed for histology studies. Sections were stained with hematoxylin and eosin and scanned using a ScanScope XT scanner (Aperio Technologies, Vista, California, USA). Images were visualized with Spectrum software (Aperio).
Comparative genomic hybridization array
A total of 0.5 mg of DNA from cell lines and female control gDNA (Promega, Madison, Wisconsin, USA) were digested by AluI and RsaI restriction enzymes and then labeled with Cy5 and Cy3, respectively, using the Enzymatic Labeling kit from Agilent, according to the manufacturer's protocol. Samples were combined, heatdenatured, and mixed with COT-1 DNA (Roche), blocking buffer, and Hi-RPM buffer (both from Agilent) before being hybridized in an Agilent 4 Â 44 k human comparative genomic hybridization (CGH) microarray for 24 h at 651C. Washing was performed as recommended by the vendor, and the arrays were scanned using an Agilent DNA microarray scanner. Data were processed using the Feature extraction Software version 10.7.3.1 and analyzed in DNA Analytics version 4.0.76 (Agilent Technologies).
Statistics
Averages of measureable variables were compared between experimental groups using Student's t-test with a 95% confidence interval. P-values of less than 0.05 were considered significant. The survival experiment was analyzed using the Kaplan-Meier method. All analyses were performed with Prism 3.0 (GraphPad, La Jolla, California, USA).
Results
Injection of a kisspeptin analog does not reduce metastasis of C8161.9 cells
We used an analog of KP to inhibit the metastatic growth of C8161.9 cells in nude mice to determine whether pharmacologic administration of KP could reproduce the antimetastatic effect seen when expression was programmed in tumor cells. Using the same xenograft model, the secretion of KP by clones of C8161.9-KFM cells was previously shown to inhibit metastasis to the lungs by more than 90% [26] . This established model used the polyclonal C8161.9-pc3 cells as a positive control for metastasis. Both pc3 and KFM cells expressed EGFP to allow ex-vivo localization of tumor cells in organs. We selected the analog FTM145 because of its resistance to proteolytic cleavage and its extended half-life in mouse serum [28] . We first confirmed that the injectable solution of the C-amidated version of FTM145 was fully active in vitro. Serial dilutions of KP10, FTM145, and the carboxylated version of FTM145 were added to HEK-293 cells expressing GPR54, and cell lysates were analyzed by western blotting for activation of ERK1/2. KP10 and FTM145 were equally potent, with full phosphorylation of ERK achieved at 1 nmol/l of each ligand. In contrast, the nonamidated FTM145 only induced significant activation of GPR54 at 1 mmol/l (Fig. 1a) .
Two groups of 20 nude mice each were injected on day 1 with metastatic C8161.9-pc3 cells (intravenous). FTM145 (amidated, n = 20) or PBS alone (n = 20) were administered daily through subcutaneous injection. In this survival experiment, FTM145 did not provide any advantage compared with injection of PBS (Fig. 1b) . Upon dissection, all animals showed extensive metastasis to the lungs (comparable with the animal shown in Fig. 3b and c, pc3 panels), irrespective of the treatment received, indicating that injection of a KP mimetic was incapable of inhibiting metastasis of C8161.9.
C8161.9-KISS-FLAG-metastin cells differ phenotypically from original C8161.9 cells
In an attempt to reconcile the data showing the absence of in-vivo activity of FTM145 with the previously published data showing the strikingly reduced metastatic potential of C8161.9 cells secreting KPs, we conducted a series of experiments comparing the in-vitro and in-vivo phenotypes of different types of C8161.9 cells: (i) parental C8161.9 cells, (ii) C8161.9 transfected with an empty pcDNA3 plasmid, selected with G418, and then transduced with a lentivirus encoding EGFP (C8161.9-pc3), and (iii) C9161.9 transfected with pcDNA3 coding for KFM, cloned, and then transduced with a lentivirus encoding EGFP (C8161.9-KFM). C8161.9-pc3 and C8161.9-KFM were used in previously published in-vivo experiments [26] , and C8161.9-pc3 were used as metastatic cells throughout the current study to remain consistent with published work.
Although both parental C8161.9 (not shown) and C8161.9-pc3 (Fig. 2a) consisted of a vast majority of small cells and a minority of larger cells, C8161.9-KFM were much larger and very homogeneous in size and morphology (Fig. 2a) . The three cell types were tested for their capacity to form colonies in soft agar. In three separate experiments, C8161.9-pc3 cells did not form any colonies, in contrast with C8161.9-KFM cells, which consistently established large numbers of colonies (Fig. 2b) . The parental C8161.9 cells formed a few colonies, but these colonies were similar in size to those made by KFM cells. Seven colonies (most likely clones, each one originating from a single cell on the basis of the distance separating the colonies as well as their spherical geometry) were isolated from the soft-agar plate with a pipette tip and expanded in culture. All seven clones (agar clones AC1-7) were composed of large cells that were morphologically similar to C8161.9-KFM cells, as shown in Fig. 2a for AC4 and AC5. After expansion, these clones maintained their capacity to form colonies in soft agar, AC5 being as efficient as KFM cells (Fig. 2c) . All cell types displayed the same growth rate under normal culture conditions with a doubling time of 24 h (not shown). These data suggest that the parental C8161.9 cells contain multiple populations with varying behaviors, including a few larger cells capable of establishing colonies in soft agar. It seems like these cells were preferentially selected in the cloning process leading to the isolation of C8161.9-KFM cells and also seem to have been depleted (partially or completely) during the selection of the C8161.9-pc3 cells.
C8161.9-KFM cells were previously described as being able to establish orthotopic tumors with an efficiency similar to that of C8161.8-pc3 cells [26] 
4 C8161.9-pc3 cells alone (Fig. 3a) , indicating that, despite an initial numerical excess, C8161.9-KFM cells were unable to inhibit the growth of C8161.9-pc3 cells.
Soft-agar clones reproduce the phenotype of C8161.9-KISS-FLAG-metastin cells
After having established that the soft-agar clones obtained from the original C8161.9 cells behaved similarly to KFM cells in vitro, we conducted experiments to test whether they also exhibited a decreased metastatic potential. Nude mice (n = 4 for each cell type) received an intravenous injection of C8161.9-pc3, C8161.9-KFM, or one of five soft-agar clones (AC2, 3, 4, 5, and 7). After 5 weeks, mice injected with pc3 cells were visibly sick, whereas all other mice appeared completely healthy. Upon dissection, mice injected with pc3 cells showed extensive metastasis to the lungs ( Fig. 3b and Table 1 ). All other cell types showed a dramatically reduced metastasis with no or very few visible lesions (Fig. 3b) . Lungs of all animals were fixed in PFA and sections were stained with hematoxylin and eosin. Analysis of these sections confirmed the dramatic reduction of metastasis observed with the KFM cells and AC2, 3, 4, 5, and 7. Representative fields of sections are shown in Fig. 3c . To rule out the possibility that the decrease of metastatic potential by these clones was due to endogenous expression of KISS1, we performed qPCR. KISS1 mRNA could be detected at high levels in the transfected KFM cells but was absent or expressed at a very low level in the soft-agar clones (Fig. 3d) as well as Jurkat cells transfected with GPR54 that do not express KISS1 and were shown to be extremely sensitive to exogenous KP10 [24] . These data indicate that clonal selection in soft agar did not select for cells overexpressing KISS1. These data indicate that a minor 
C8161.9-KFM cell clone differs morphologically and phenotypically from the majority of the parental cell line. (a) C8161.9-pc3 cells and the parental cell line (not shown) consisted mostly of small cells, whereas the poorly metastatic C8161.9-KFM clone described previously was homogenously constituted of larger cells. Clones isolated in soft-agar culture from the parental C8161.9 cell line shared similarly large sizes. (b) C8161.9-KFM cells, but not C8161.9-pc3, developed large numbers of colonies in soft agar. In contrast, parental C8161.9 cells only formed seven colonies that were isolated and amplified (AC1-7). Images were taken using an inverted microscope with a Â 10 objective.
(c) After in-vitro amplification, clones isolated in soft agar from parental C8161.9 cells maintained the capacity to form colonies in soft agar, with an efficiency ranging from moderate (AC4) to as high as C8161.9-KFM cells (AC5). Pictures of the whole plates were taken with a GE LAS-4000 imaging system. AC, agar clones; KFM, KISS-FLAG-metastin.
subpopulation of cells present in the parental C8161.9 cell line phenotypically resembles C8161.9-KFM cells (both in morphology and in tumor-forming potential) without expressing KISS1. They also illustrate an inverse relationship between the clonogenicity in soft agar and the capacity to form tumors in nude mice. Single-cell cloning of C8161.9 cells is biased toward large cells similar to KISS-FLAG-metastin cells
As the KP-expressing cells already available displayed a phenotype that did not represent the original C8161.9 cell line, we sought to prepare new transfectants expressing KISS1 using parental C8161.9 cells or C8161.9-pc3 cells. To remain as close as possible to the original model, we designed two parallel strategies. First, to derive new transfectants from cells with a tested and well-established metastatic potential, we used as host the C8161.9-pc3 transfectants that have previously been used in animal experiments, including those described above. As these cells were already resistant to G418, we used the hygromycin pcDNA3 vector to stably introduce KFM in these cells. In the second strategy, we established new transfectants from the parental C8161.9 cell line using G418 as a selection marker to exactly reproduce the conditions that presided over the creation of the pc3 and KFM cells described and employed previously. As every single cell injected into the animals for the xenograft studies must secrete KISS1, antibiotic selection is not sufficient and single-cell cloning is required to guarantee homogeneity of the cell population. Cells were transfected with pcDNA3.1-KFM-G418 (for parental C8161.9) or pcDNA3.1-KFM-Hygro (for C8161.9-pc3), both plasmids containing an insert coding for KFM identical to that employed by Nash et al. [26] . After selection with G418 (for parental cells) or hygromycin (for C8161.9-pc3 cells), stable KFM transfectants were obtained by single-cell cloning. We first used limiting dilution in 96-well plates, which produced only two clones out of six plates (576 wells) for the parental cells and three clones out of 12 plates (1152 wells) for the pc3 cells. Each of these clones consisted of large cells similar to the C8161.9-KFM cells used previously (not shown).
The very low number of clones obtained and the recurring 'large-cell' phenotype indicate that C8161.9 cells are very difficult to clone and that standard protocols are heavily biased toward the selection of large cells that seem to be the only ones capable of growing at a very low density. Because this bias increased the risk of selecting cells that functionally did not represent the C8161.9 cell line as a whole, these few clones were discarded without further study.
To avoid this problem and obtain multiple clones representing the diversity of C8161.9 cells, we used a 'feedercell' approach in which transfected cells (10 cells/ml) were mixed with nontransfected C8161.9 cells (1 Â 10 4 /ml) before seeding (100 ml/well), so that transfectants could establish supportive contacts with neighboring cells. After 6 days of coculture in complete medium without selection antibiotics, cells were about 50% confluent. At this point, G418 or hygromycin was reintroduced in the growth medium, eliminating all the nontransfected cells in 2 or 3 days. Resistant clones were left to expand and were detected under an inverted microscope. Supernatants were collected and tested by ELISA for the presence of secreted KFM. More than 125 clones were obtained from five 96-well plates, indicating that this protocol allowed the isolation of positive clones with no or minimum selective pressure other than the selection antibiotic. The clones displayed a variety of morphologies, most consisting of small cells and a few composed of large cells, thus demonstrating the heterogeneity of the original cell line (not shown).
Clones positive for secretion of KFM (over 40) were expanded and further tested for expression of KFM by flow cytometry and semiquantitative ELISA. Flow cytometry allowed the selection of genuine single-cell clones with homogeneous expression of intracellular KFM (Fig. 4a) . Some clones displayed expression as high as the original C8161.9-KFM clone. Secretion of KFM was assessed by semiquantitative ELISA. Representative clones are shown in Fig. 4b .
New C8161.9-KISS-FLAG-metastin clones show normal metastatic potential
The metastatic potential of the new C8161.9 clones expressing high levels of KFM was evaluated in nude mice. A total of 17 clones were tested, either as individual clones (eight clones) or as pools of two to four clones (nine clones in three pools; Table 1 ). Two or four nude mice were injected intravenously with 5 Â 10 5 cells and were killed after 5 weeks. The lungs of mice injected with large-cell variants (clones 2E8 and 5C6) showed strongly decreased metastasis compared with mice injected with C8161.9-pc3 cells, whereas mice injected with clones composed of small cells that resembled the parental line showed extensive metastasis similar to that obtained with pc3 cells, independent of the KFM expression level (Fig. 4c and Table 1 ). Although the number of animals used for each clone is small, data were very consistent for each clone and within each phenotype (small vs. large cells). Only one small-cell clone (4F12) showed a decreased number of metastatic lesions (although most lesions were large) (Fig. 4c) . These data show that the C8161.9 cell line consists of multiple subpopulations with different metastatic potentials and that individual clones can exhibit in-vivo clonogenic activities resulting in a metastatic potential ranging from very high to very low, independent of KP expression.
Morphological differences correlate with genomic changes in C8161.9 cells evident following selection
Having established a correlation between cell morphology and cell phenotype in vitro and in vivo, we hypothesized that this phenotypic heterogeneity could also be evidenced at a genetic level. We used CGH with highresolution DNA microarrays to detect DNA copy-number variations (CNV; gains and losses) in nine different C8161.9 variants: parental C8161.9, C8191.9-pc3 and the new KFM clone 6F10 for the small-cell/highly metastatic category, C8161.9-KFM (the original clone used by Nash 
Neg clone
Metastatic potential of new C8161.9 clones is independent from KISS1 expression. New clones of C8161.9 cells expressing KFM displayed a wide range of metastatic potential related to cell morphology but independent of KFM expression. Multiple new C8161.9 single-cell clones were derived after transfection with pcDNA3.1-KFM and limiting dilution using nontransfected feeder cells. (a) These new clones were tested by flow cytometry for expression of intracellular KFM using a mAb specific for KISS1 (1D5). The histograms show, for each clone, a single population with a staining intensity similar to the previously described C8161.9-KFM cells. (b) Semiquantitative ELISA for KFM secretion was performed on conditioned media obtained with new KFM clones (shown: clones 2E8, 4F12, 5G9, 1A4, 6F10, and 6B6) in comparison with two conditioned media obtained with the original C8161.9-KFM clone described previously. Results showed similar levels of secretion of KFM for the different clones. (c). Representative sections of lungs from mice inoculated in the tail vein with new KFM clones and collected after 5 weeks. Clones consisting of large cells similar to KFM cells (e.g. 2E8) had strongly reduced metastasis, whereas clones consisting of smaller cells similar to pc3 cells (e.g. 6F10) maintained aand colleagues), and soft-agar clones AC2, 3, 4, 5 and 7 for the large cell/poorly metastatic category. Data analysis indicated that although some CNV shared by all cell types from both groups (gain of chromosome 3q and loss of 9p and 17q) indicate a common origin, members of the large cell group shared additional CNV that were absent in small cells and could not be detected in parental C8161.9 cells or C8161.9-pc3 cells, such as loss of chromosomes 4, 5p, 5q, 9p, and 17p, as well as gain of chromosomes 9q and 17q (Fig. 5) . The fact that these CNV could not be detected in the parental cell line correlates with the fact that the vast majority of the cells in the C8161.9 cell line consists of small cells and that the large-cell variants represent a minor population. These data also show that the C8161.9-KFM clone used in the previous study differed from the original C8161.9 cell line at several genomic and phenotypic levels in a manner unrelated to KISS1 expression.
Discussion
Among the members of the family of metastasis suppressors, expression of KISS1 was shown to confer dramatic inhibition of the postmigratory step of the metastatic process. The initial studies for characterizing the mechanisms responsible for the antimetastatic effect assumed an autocrine mechanism of action whereby KP secreted by tumor cells would bind and activate GPR54 on the same cells, thereby inhibiting cell migration as shown with the B16 model of melanoma [19] . The C8161.9 model indicated instead that expression of GPR54 on the tumor cells was not required for KISS1 suppression of metastasis [26] . The observation that secretion of KISS1 by C8161.9 melanoma cells maintained the cells in a prolonged state of dormancy opened new perspectives toward the therapeutic use of KP molecular analogs that could be used to treat metastatic disease even after the initial spread of tumor cells. As these findings also suggested that the target of KISS1 was the microenvironment, the C8161.9 model represented an appropriate system to investigate this hypothesis. However, administration of high concentrations of a fully active KP10 analog with vastly improved resistance to proteolytic degradation failed to reduce metastasis of C8161.9 cells in nude mice. In addition, C8161.9-KFM established orthotopic tumors much more slowly than control C8161.9-pc3 cells and failed to inhibit the growth of pc3 when locally coinjected with a 10 : 1 excess. Although these data could be explained (insufficient local concentration of the analog, action of KISS1 mediated by a proteolytic fragment other than KP, KFM cells quickly outgrown by pc3 cells in the mixing experiment), they together prompted us to reconsider the validity of the C8161.9 model.
Here we present evidence that the C8161.9-KFM described previously as being poorly metastatic shared in-vitro features with a cell population present at low frequency (seven clones obtained in soft-agar culture from 1.5 Â 10 4 cells), which could be derived from the parental cell line. Although it also exhibited some level of internal heterogeneity, as a whole, this subpopulation consisted of larger cells that had the capacity to form colonies in soft agar, could grow as single cells in vitro, and had the same in-vitro growth rate as smaller cells, but grew very poorly in vivo when grafted in nude mice, even in the absence of KISS1 expression. In contrast, the predominant population of C8161.9 cells were smaller, did not form colonies in soft agar, and could not be cloned using standard limiting dilution protocols, but were highly tumorigenic in mice. On the basis of these differences in growth properties, standard selection procedures using selectable markers and single-cell cloning favor the outgrowth of the nonmetastatic population. These two distinct cell populations (large and mostly small cells) also segregate in two different categories at the genomic level, thus mirroring and substantiating the phenotypic differences. The very strong bias toward the selection of large nonmetastatic/ nontumorigenic cells during the cloning process is most likely the reason for the previous description of the antimetastatic effect of the secretion of KFM. This was confirmed by showing that multiple new clones obtained without the bias of that selective pressure and expressing high levels of KISS1 maintained the metastatic potential of the parental cell line. The amount of metastasis was measured using the Aperio digital pathology system and is indicated as follows: -, no visible metastasis; + / -, 0 or 1 very small metastatic lesion (< 10 cells) per section; + , 1-5 small lesions (< 20 cells) per section, representing less than 1% of the surface area of the lung tissue in the section; + + , 1-10 lesions per section, representing in total <10% of the surface area; + + + , multiple lesions representing 10-25% of the surface area; + + + + , multiple lesions representing in total >25% of the lungs surface area (often >50%). CGH types 1 and 2 refer to the typical profiles illustrated in Fig. 5 . AC, agar clones; CGH, comparative genomic hybridization; KFM, KISS-FLAGmetastin.
Our data do not necessarily disprove that KISS1 is a metastasis suppressor in melanoma and other cancers, even though its role in the C8161.9 xenograft model appears to be unclear. Indeed, numerous studies investigating the expression of KISS1 and GPR54 in human samples suggest that this system plays a role in a number of malignancies, although a more limited one than what was suggested by the C8161.9 model. Some studies also support the hypothesis of an affect of KISS1 on the microenvironment, especially on angiogenesis. In particular, KISS1 was shown to trigger vasoconstriction by acting on smooth-muscle cells [29] . Another recent study indicated KISS1 signaling in endothelial cells and the resulting inhibition of angiogenesis [30] . The results presented here show that the C8161.9 xenograft model does not constitute an appropriate system to investigate the mechanism of action of KISS1. They especially highlight the risk of experimental artifacts resulting from the selection of single-cell clones from a cell line after transfection. When cloning is necessary -as it is in the case of selection on the basis of the expression of a secreted factor -great care should be taken to characterize the clones to prove that they faithfully represent the original cell population, both in vitro and in vivo. In that respect, the high-resolution CGH employed here represents a method of choice.
